



## **Aerus ActivePure Technology Announces SARS-CoV-2 Test Results**

Aerus ActivePure Air and Surface Purifier Provides 99.98% COVID-19 Surface Reduction Rate in Controlled, Independent Laboratory Studies

DALLAS (September 30, 2020) –, Aerus, the global leader in air and surface purification solutions, announced today that testing data conducted by independent FDA-compliant laboratory, [MRIGlobal](#), established a 99.98% surface kill rate of live SARS-CoV-2 virus in just 7 hours with the Aerus Hydroxyl Blaster air and surface purifier.

Data collected in the study showed a 93% surface kill in 3 hours and 98% surface kill in 6 hours of live SARS-CoV-2, even when covered by a protective biofilm, with the Aerus Hydroxyl Blaster and its patented ActivePure Technology.

In addition, Aerus is running independent laboratory tests to demonstrate the efficacy of ActivePure Technology on airborne SARS-CoV-2 virus. These results will be submitted to the FDA for review and clearance. Aerus Technology has a 99.9999% kill rate of airborne RNA viruses in just 60 minutes and 99.999% in 30 minutes, as proven with the FDA 510(k) cleared Aerus Medical Guardian with ActivePure, and performs materially faster on airborne pathogens while it simultaneously destroys surface pathogens. The patented, photocatalyst ActivePure Technology in the Aerus Hydroxyl Blaster is the same ActivePure Technology used in the Aerus FDA Class II Medical Device, the [Aerus Medical Guardian](#).

Aerus is confident its upcoming SARS-CoV-2 RNA virus airborne tests will demonstrate strong performance both in speed and the reduction level of the SARS-CoV-2 virus in the air, based on the airborne test results with non-lipid surrogate, MS2 Bacteriophage RNA virus. The SARS-CoV-2 RNA virus is a lipid virus, which the FDA has acknowledged is easier to destroy than non-lipid viruses. Aerus is working expeditiously to confirm the airborne disinfection rate on the SARS-CoV-2 virus. When available, this data will be submitted to the FDA for clearance.

Aerus is awaiting final approval from the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) for the Aerus Hydroxyl Blaster with ActivePure Technology for use in reducing SARS-CoV-2 surface pathogens. The results have also been submitted by Aerus to the FDA-equivalent Canadian and European Union regulators, requesting that they clear Aerus ActivePure devices to combat the SARS-CoV-2 coronavirus. Aerus expects to receive clearances in all jurisdictions in the near future.



*Aerus Hydroxyl Blaster with ActivePure Technology*

Aerus ActivePure's patented honeycomb matrix located inside Aerus' air purification devices creates powerful oxidizers, known as ActivePure Molecules, or hydroxyls, that are released back into the air space where they seek and destroy RNA and DNA viruses and pathogens on surfaces and in the air, regardless of their size, and do so safely with people in the room. The viruses successfully tested and destroyed by ActivePure Technology include SARS-CoV-2, Swine Flu (H1N1), Avian Bird Flu (H5N8), Hepatitis A (HAV), MS2 Bacteriophage, and Murine Norovirus, as well as other contaminants including Staphylococcus Epidermidis, MRSA, E Coli, C Diff, Hepatitis A, Aspergillus Niger Fungal, black mold, legionella pneumophila, and Volatile Organic Compounds.

There are many capture-based air purifiers on the market that rely solely on a HEPA filter, carbon filter, ultraviolet light, or passive PCO to reduce contaminants in an indoor space. However, these units, by design, are only partially effective at reducing some of the airborne pathogens that are captured or pulled through the system and are not effective at treating the entire air space in real time. Furthermore, none of these solutions address surface viruses or contaminants. Other devices such as bi-polar ionization have questionable results, as indicated by the CDC and ASHRAE. ActivePure Molecules created by ActivePure Technology continuously seek out and destroy viral particles the size of the SARS-CoV-2 novel coronavirus – typically ranging from 0.06 to 0.14 microns – without the need for a limiting capture-based filter, such as HEPA.

"Aerus' results are a gamechanger in America's battle against COVID-19. Our technology has the potential to minimize community exposure indoors of the SAR-CoV-2 virus on surfaces and in the air," said Joe Urso, Chief Executive Officer of Aerus. "The efficacy of our data is consistent with our other previously reported RNA and DNA virus data and confirms that ActivePure Technology used in our purification systems is the fastest-acting decontaminator available for use on both surface and airborne pathogens, and it operates continuously, 24/7, and safely in occupied spaces. We are beyond pleased to announce these important COVID-19 disinfection results with our ActivePure Technology purification solutions."

The ActivePure Technology air and surface disinfecting and purifying system is the safest, fastest and most powerful surface and air purification technology available that minimizes recontamination and cross contamination in real time, safely in occupied spaces, without the use of chemicals or ozone. Once inactivated, pathogens are reduced to safe and inert byproducts. ActivePure Technology is Certified Space Technology and was honored as an inductee to the Space Technology Hall of Fame in 2017; 1 of only 75 technologies to be inducted in the past thirty years.

The Aerus Hydroxyl Blaster with patented ActivePure Technology is a free-standing portable air and surface purification system intended for the reduction of the SARS-CoV-2 coronavirus and other contaminants in large, occupied indoor spaces of up to 20,000 square feet. The Aerus Hydroxyl Blaster is designed, engineered, and manufactured in the USA.

ActivePure Technology is available in over 70 Aerus products, both portable and installed for every environment, and is sold by a limited number of companies.

Aerus is committed to the scientific integrity of its R&D programs and has invested heavily in the careful verification of its reported findings through independent, controlled laboratory testing.